- Home
- IBIO vs AIMD Comparison
IBIO vs AIMD Comparison
Compare IBIO & AIMD Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- IBIO
- AIMD
- Stock Information
- Founded
- IBIO 2008
- AIMD 1984
- Country
- IBIO United States
- AIMD United States
- Employees
- IBIO N/A
- AIMD N/A
- Industry
- IBIO Biotechnology: Pharmaceutical Preparations
- AIMD Biotechnology: Pharmaceutical Preparations
- Sector
- IBIO Health Care
- AIMD Health Care
- Exchange
- IBIO Nasdaq
- AIMD Nasdaq
- Market Cap
- IBIO 9.3M
- AIMD 8.2M
- IPO Year
- IBIO N/A
- AIMD N/A
- Fundamental
- Price
- IBIO $0.98
- AIMD $0.66
- Analyst Decision
- IBIO Strong Buy
- AIMD
- Analyst Count
- IBIO 3
- AIMD 0
- Target Price
- IBIO $4.87
- AIMD N/A
- AVG Volume (30 Days)
- IBIO 455.0K
- AIMD 393.2K
- Earning Date
- IBIO 05-02-2025
- AIMD 08-04-2025
- Dividend Yield
- IBIO N/A
- AIMD N/A
- EPS Growth
- IBIO N/A
- AIMD N/A
- EPS
- IBIO N/A
- AIMD N/A
- Revenue
- IBIO $375,000.00
- AIMD $106,207.00
- Revenue This Year
- IBIO $36.00
- AIMD N/A
- Revenue Next Year
- IBIO N/A
- AIMD N/A
- P/E Ratio
- IBIO N/A
- AIMD N/A
- Revenue Growth
- IBIO 650.00
- AIMD 13.38
- 52 Week Low
- IBIO $0.64
- AIMD $0.40
- 52 Week High
- IBIO $6.89
- AIMD $1.17
- Technical
- Relative Strength Index (RSI)
- IBIO 48.45
- AIMD 60.11
- Support Level
- IBIO $0.75
- AIMD $0.62
- Resistance Level
- IBIO $1.03
- AIMD $0.80
- Average True Range (ATR)
- IBIO 0.08
- AIMD 0.07
- MACD
- IBIO 0.08
- AIMD 0.01
- Stochastic Oscillator
- IBIO 75.74
- AIMD 60.64
About IBIO iBio Inc.
iBio Inc is a preclinical stage biotechnology company that leverages the power of Artificial Intelligence (AI) for the development of precision antibodies. CDMO. Its technology stack is designed to minimize downstream development risks by employing AI-guided epitope-steering and monoclonal antibody (mAb) optimization.
About AIMD Ainos Inc.
Ainos Inc is engaged in developing biologics for the treatment of human and animal diseases. The company mainly focuses on the research of the treatment of human disease indications, particularly influenza, hepatitis C, thrombocytopenia, and other indications using natural human interferon-alpha that is administered in a proprietary low-dose oral form. Its product pipeline includes VELDONA Pet cytoprotein supplements for pets, VELDONA human therapeutics for clinical use, and telehealth-friendly POCTs powered by the AI Nose technology platform.